BEPREVE Drug Patent Profile
✉ Email this page to a colleague
When do Bepreve patents expire, and what generic alternatives are available?
Bepreve is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has eleven patent family members in eight countries.
The generic ingredient in BEPREVE is bepotastine besilate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bepotastine besilate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bepreve
A generic version of BEPREVE was approved as bepotastine besilate by APOTEX on March 5th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BEPREVE?
- What are the global sales for BEPREVE?
- What is Average Wholesale Price for BEPREVE?
Summary for BEPREVE
International Patents: | 11 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 80 |
Clinical Trials: | 7 |
Patent Applications: | 139 |
Drug Prices: | Drug price information for BEPREVE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BEPREVE |
What excipients (inactive ingredients) are in BEPREVE? | BEPREVE excipients list |
DailyMed Link: | BEPREVE at DailyMed |
Recent Clinical Trials for BEPREVE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Southern California College of Optometry at Marshall B. Ketchum University | Phase 4 |
Southern California College of Optometry | Phase 4 |
McCabe Vision Center | N/A |
Pharmacology for BEPREVE
Drug Class | Histamine-1 Receptor Antagonist |
Paragraph IV (Patent) Challenges for BEPREVE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
BEPREVE | Ophthalmic Solution | bepotastine besilate | 1.5% | 022288 | 3 | 2013-09-09 |
US Patents and Regulatory Information for BEPREVE
BEPREVE is protected by one US patents.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | AT | RX | Yes | Yes | 8,784,789 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BEPREVE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | 6,780,877 | ⤷ Subscribe |
Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | 8,877,168 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BEPREVE
See the table below for patents covering BEPREVE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 101016595 | ⤷ Subscribe | |
Japan | 2016006059 | 光学活性ピペリジン誘導体の酸付加塩及びその製法 (OPTICALLY ACTIVE PIPERIDINE DERIVATIVE ACID-ADDITION SALT AND PREPARATION THEREOF) | ⤷ Subscribe |
Japan | 2007145852 | ACID ADDUCT SALT OF OPTICALLY ACTIVE PIPERIDINE DERIVATIVE AND METHOD FOR PRODUCING THE SAME | ⤷ Subscribe |
Japan | 2000159762 | OPTICAL RESOLUTION OF PIPERIDINE DERIVATIVE | ⤷ Subscribe |
China | 1446812 | ⤷ Subscribe | |
Japan | 2014012732 | ACID ADDITION SALT OF OPTICALLY ACTIVE PIPERIDINE DERIVATIVE AND MANUFACTURING METHOD THEREOF | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
BEPREVE Market Analysis and Financial Projection Experimental
More… ↓